In situ cellular immune response in non-ulcerated skin lesions due to Leishmania (L.) infantum chagasi infection

Carmen Sandoval¹, Gabriela Araujo¹, Wilfredo Sosa¹,², Sara Avalos³, Fernando Silveira⁴,⁵, Carlos Corbett¹, Concepción Zúñiga⁶, Marcia Laurenti¹*

¹Laboratory of Infectious Diseases Pathology, Department of Pathology, Medical School (FMUSP), University of São Paulo (USP), São Paulo, SP, Brazil.
²Microbiology Research Institute, National Autonomous University of Honduras, Tegucigalpa, Honduras.
³Master Program in Infectious and Zoonotic diseases, School of Microbiology, National Autonomous University of Honduras, Tegucigalpa, Honduras.
⁴Department of Parasitology, Evandro Chagas Institute, Secretariat of Health Surveillance, Ministry of Health, Belém, PA, Brazil.
⁵Institute of Tropical Medicine, Federal University of Pará, Belém, PA, Brazil.
⁶Department of Health Surveillance, School Hospital, Tegucigalpa, Honduras.

Abstract
Background: Skin lesions of patients affected by non-ulcerated cutaneous leishmaniasis (NUCL) caused by L. (L.) infantum chagasi are characterized by lymphohistiocytic inflammatory infiltrate associated with epithelioid granuloma and scarce parasitism. However, the in situ cellular immune response of these patients is unclear. Therefore, the aim of the present study was to characterize the cellular immune response in the skin lesions of patients affected by NUCL.

Methods: Twenty biopsies were processed by immunohistochemistry using primary antibodies to T lymphocytes (CD4, CD8), NK cells, B lymphocytes, macrophages, nitric oxide synthase and interferon-gamma.

Results: Immunohistochemistry revealed higher expression of all cellular types and molecules (IFN-γ, iNOS) in the dermis of diseased skin compared to the skin of healthy individuals (p < 0.05). Morphometric analysis performed in the skin lesions sections showed the predominance of CD8⁺ T lymphocytes in the mononuclear infiltrate, followed by macrophages, mostly iNOS⁺, a response that could be mediated by IFN-γ.

Conclusion: Our study improves knowledge of the cellular immune response in non-ulcerated or atypical cutaneous leishmaniasis caused by L. (L.) infantum chagasi in Central America and pointed to the pivotal participation of CD8⁺ T lymphocytes in the host defense mechanisms against the parasite in patients with NUCL.

Keywords:
Non-ulcerated cutaneous leishmaniasis
Atypical cutaneous leishmaniasis
Leishmania infantum chagasi
Cellular immune response
Immunohistochemistry
Honduras

* Correspondence: mdlauren@usp.br
https://doi.org/10.1590/1678-9199-JVATITD-2020-0149
Received: 13 October 2020; Accepted: 25 January 2021; Published online: 26 February 2021

On-Line ISSN 1678-9199 © The Author(s). 2021 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Leishmania (L.) infantum chagasi is etiological agent of visceral leishmaniasis (VL) in America. However, in some countries of Central America – including Costa Rica, Nicaragua, El Salvador and Honduras – this parasite specie besides VL also causes atypical or non-ulcerated cutaneous leishmaniasis (NUCL) [1–5]. It is important to mention that both VL and NUCL do not occur at the same time in the same patient. Usually NUCL affects children over 5 years old and young adults and VL children under 5 years old [4,6].

NUCL have been reported since the 1990s in Honduras, when an increased number of non-ulcerated lesions was observed in endemic areas of L. (L.) infantum chagasi transmission. Non-ulcerated nodules or papules of small size, generally surrounded by a hypopigmented halo, mainly located in exposed areas of the body, and habitually of chronic evolution, characterize these cutaneous lesions. Campos-Ponce et al. [7] suggest that the L. (L.) infantum chagasi tropism to viscera or skin observed in Honduras could be strongly related to the immunological background of the patients, since genotypic differences among parasites strains were reported [1,2]. It must be highlighted that cutaneous lesions caused by L. (L.) infantum chagasi have already been described in South America, but the reports related to ulcerated lesions are different from those observed in Central America, which independently of the time of evolution do not ulcerate [8–11].

Microscopically, NUCL skin lesions are characterized by a mononuclear inflammatory infiltrate in the dermis of variable intensity, formed mainly by lymphocytes and macrophages, associated with epithelioid granuloma and scarce parasitism. The epidermis preserved and only slight thinning is observed in some cases [12]. Among to lymphocytes subpopulation, the involvement of the Th17 cells in NUCL skin lesion has recently been described [13], indicating that the presence of Th17 lymphocytes could play a pro-inflammatory role promoting the control of tissue parasitism. However, despite the participation of the Th17 inflammatory response, the total control of tissue parasitism and the spontaneous healing of the lesion does not occur; probably, due the participation of regulatory immune response (FoxP3 + cells), mainly through the production of TGF-β [14].

There are scarce reports relating histopathological features or cellular immune response of the skin lesion caused by L. (L.) infantum chagasi in America. Therefore, to deepen our knowledge on aspects of in situ cellular immunity to better understand the clinical aspects of disease, the present study characterized CD4 and CD8 T lymphocytes, B lymphocytes, NK cells, macrophages, as well as elements of activation such as IFN-γ and iNOS in skin lesions of patients with non-ulcerated cutaneous leishmaniasis provoked by L. (L.) infantum chagasi using immunohistochemistry.

Methods

Patients and samples

Twenty biopsies of skin lesions from patients with NUCL from an area of L. (L.) infantum chagasi transmission located in the south Honduras, municipalities of Amapala and Orocuina, were used. None of the patients included in this study had a previous history of VL, nor received treatment for leishmaniasis. All patients presented positive parasitological diagnosis in scrapings of lesions stained by Giemsa, and L. (L.) infantum chagasi was characterized by RT-PCR [12]. The present study was approved by two institutional ethics committees (research protocols #03-2014 and #051/15). Informed consent was obtained from all participants in the study. As already reported [12], from 20 NUCL patients, 100% presented non-ulcerated cutaneous lesions (Figure 1), 65% were women and 20% were men. Gender was not reported in 15% of the patients. The average age was 33.4 years, ranging from 9 to 70 years. The evolution time of lesions varied from 1 to 240 months. About 70% of the lesions had a diameter of 3 to 5 mm, and the majority were unique. The lesions were located on the extremities (arms and legs) or face. After diagnosis and biopsies collection, all patients included in this study received treatment according to the protocol handled by the Ministry of Health of Honduras [3].

Immunohistochemistry study

The in situ cellular immune response was characterized by immunohistochemistry. Briefly, we performed the tissue deparaffinization and hydration, blockade of the endogenous peroxidase in 3% hydrogen peroxide, and antigen recovery using citrate buffer (10 mM/pH 6.0) in a boiling water bath for 30 min. After, the samples were incubated overnight at 4 °C with the following primary antibodies: CD4 (monoclonal, NCL-L-CD4-1F6, Novocastra), CD8 (monoclonal, NCL-L-CD8-295, Novocastra), CD20 (polyclonal, (C-20): SC-7733, Santa Cruz Biotechnology), CD56 (monoclonal, NCL-L-CD56-504, Novocastra), CD68 (monoclonal, ab955, ABCAM), iNOS (polyclonal, (N-20): SC-651, Santa Cruz Biotechnology) and IFN-γ (polyclonal, (H-145): SC-8308, Santa Cruz Biotechnology) at 1:20, 1:100, 1:1000, 1:100, 1:400, 1:200 and 1:100 dilutions, respectively. Isotype controls were used as negative controls. For all markers, the Novolink Kit (RE7280-K-Leica) was used. All reactions were developed using a chromogenic substrate, DAB+H2O2 (diaminobenzidine with hydrogen peroxide-K3468-Dako Cytomation), followed by Harris haematoxylin counterstaining. Finally, the slides were dehydrated in a series of ascending alcohols and mounted with Permount and a glass coverslip. Tonsil sections were used as positive controls. Cells marked in brown were considered positive.

Ten skin samples obtained from healthy individuals undergoing plastic surgery were included as controls.
Quantitative morphometric analysis of immunostained cells

Ten sequential fields of each histological section (objective 40×) were photographed in an optical microscope coupled to the computer using the AxioVision 4.8 software (Zeiss). Brown-immunostained cells were quantified, taking into account the cell colour pattern and morphology for each antibody using ImageJ software. The determination of the cell density (cells per square millimeter) of each marker was calculated by the ratio between the immunostained cells and the area of each photo.

Statistical analysis

Statistical analysis was performed with GraphPad Prism 5.0 software. We used the Kolmogorov-Smirnov test to normality test, the t-test for data with a Gaussian distribution, the Mann-Whitney test for those without normal distribution, and the Spearman and Pearson tests to correlate the different immunohistochemical markers.

Results

Immunohistochemical analysis

The skin lesions of patients with NUCL showed the presence of all the markers in the dermal mononuclear infiltrate, B lymphocytes (CD20+), CD4+ and CD8+ T lymphocytes, NK cells (CD56+), macrophages (CD68+), iNOS+ and IFN-γ+ cells (Figures 2 and 3).

The quantitative analysis showed that the cellular density (mean ± standard error) was 173.2 ± 56.4 for CD20+ cells, 785.8 ± 169.7 for CD8+ T lymphocytes, 296.6 ± 53.5 for CD4+ T lymphocytes, 47.8 ± 12.7 for CD56+ cells, 219.5 ± 33.7 for iNOS+ cells and 671.4 ± 124.9 cells/mm² for IFN-γ+ cells in the skin lesion of patients affected by NUCL (Figure 4A). In contrast, the cellular density of all markers in the skin of healthy individuals was lower than their observed in the skin lesions of individuals with NUCL (p < 0.05). So, the cellular density in health skin was 12.7 ± 7.9 for CD20+ cells, 15.9 ± 6.1 for CD8+ T lymphocytes, 46.2 ± 11.6 for CD4+ T lymphocytes, 1.4 ± 1.1 for CD56+ cells, 17.9 ± 8 for CD68+ cells, 0.1± 0.1 for iNOS+ cells and 7.2 ± 3.8 cells/mm² for IFN-γ+ cells (Figure 4B).

For better understanding the participation of the cellular immune response in the inflammatory infiltrate, the ratio between CD4 and CD8 T lymphocytes, as well as iNOS+ cells and macrophages (CD68) in the lesions of patients and healthy skin was evaluated. The ratio of CD4/CD8 was 8 times lower in the cutaneous lesions of NUCL patients (0.38) compared to healthy skin (2.92), pointing to the high participation of T CD8+ lymphocytes in the NUCL lesions. On the other hand, the ratio of iNOS/CD68 was 167 times higher in NUCL (1.0) than that observed in healthy skin (0.006). Considering NUCL, the ratio of IFN-γ/CD8 was 0.85, IFN-γ/CD4 was 2.26, and IFN-γ/CD56 was 14.04, suggesting that the majority of IFN-γ-producing cells are CD8 lymphocytes.

A positive correlation was observed among all the cellular markers used in this study, except for NK cells (CD56). Taking the most important correlations, a positive and strong correlation was observed between the density of CD8+ T lymphocytes and IFN-γ+ cells ($r_\chi = 0.8794$ and $p = 0.00001$); and also between CD4+ T lymphocytes and IFN-γ+ cells ($r_\chi = 0.7206$ and $p = 0.0011$). The density of macrophages (CD68+) showed a positive and strong correlation with the density of iNOS+ cells ($\rho = 0.8909$ and $p = 0.00001$), and a positive and moderate correlation was also observed between iNOS+ cells and IFN-γ+ cells ($r_\chi = 0.6520$ and $p = 0.00621$).
Figure 2. Photomicrographs of immunohistochemistry reaction in histological sections of skin lesions of patients with non-ulcerated or atypical cutaneous leishmaniasis showing in the dermal inflammatory infiltrate: (A) B lymphocytes (CD20^+); (B) NK cells (CD56^+); (C) CD4^+ T lymphocytes and (D) CD8^+ T lymphocytes.

Figure 3. Photomicrographs of immunohistochemistry reaction in histological sections of skin lesions of patients with non-ulcerated or atypical cutaneous leishmaniasis showing in the dermal inflammatory infiltrate: (A) macrophages (CD68^+); (B) IFN-γ^+ and (C) iNOS^+ cells.
Discussion

The in situ cellular immune response in cutaneous leishmaniasis caused by dermotropic strains has been widely studied. Immunological spectrum of cutaneous leishmaniasis has been observed in human disease varying from a strong T-cell response characterized by hypersensitivity with high TNF-α and IFN-γ production, with subsequent activation of macrophages and lysis of the parasite; to the lack of delayed hypersensitivity response (DTH) characterized by a Th2-type immune response, with high production of IL-4, IL-10 and TGF-β, leading to suppression of T cells and disease progression [15–17].

*L. (L.) infantum* chagasi is classically causative agent of visceral leishmaniasis, but in some regions skin lesions caused by this specie of parasite have been reported in patients with no previous history of VL. However, the clinical presentation varies depending on the region. Reports has been shown that in the Old World, the most usual clinical feature is a single lesion that consists of small, crusty ulcers surrounded by a notable erythematous reaction or non-ulcerated papules that, when ulcerated, are recovered with a discrete crust [18–22]. In some countries of South America, these lesions clinically can be papular, nodular, or ulcerated with or without the presence of crust [8–11]. However, in Central America [4,12–14,23], the patients presented small nodular lesions that do not cause ulcer independent of the evolution time of infection.

The histopathological features reported in Europe by *L. (L.) infantum* infection are characterized by slight hyperkeratosis with parakeratosis and moderate acanthosis in the epidermis; and in the dermis, the findings depend on the time of evolution of infection, in the initial phase the inflammatory infiltrate is dense and diffuse composed of parasitized histiocytes, lymphocytes, and plasma cells with a small number of eosinophils and neutrophils, in chronic lesions the inflammatory infiltrate is granulomatous, with epithelioid cells and multinucleated giant cells, with a reduction in the number of parasites [18–20,24].

On the other hand, the histopathological changes of epidermis in non-ulcerated skin lesion caused by *L. (L.) infantum* chagasi in Central America is characterized by slight thinning, mild acanthosis, and focal lymphohistiocytic exocytosis in 40%, 10% and 20% of the cases, respectively; and in the dermis a mononuclear inflammatory infiltrate formed mainly by lymphocytes followed by macrophages with very few plasma cells and scarce parasitism was observed [12].

The histopathological aspects of the skin lesion reported in the NUCL [12] differ from those described for cutaneous lesions caused by dermotropic species of the parasite in the New World, such as *L. (L.) amazonensis*, *L. (V) braziliensis* [15], *L. (V) guyanensis* [25], and *L. (V) panamensis* [26] which are characterized by evident changes in the epidermis that show the presence of ulcer, acanthosis, exocytosis, parakeratosis, and hyperplasia; and mononuclear inflammatory infiltrate varying the intensity and cellular type, granulomatous reaction and necrosis according to the time of infection and the parasite specie. These findings reinforce the role of the parasite in determining the clinical and immunohistopathological features of the infection [16]. In this sense a study using different species of viscerotropic and dermotrophic parasites reported that keratinocytes are important nontraditional immune cells that shape the local immune response to *Leishmania* species after their introduction into the skin and in concert with other local factors may contribute to development of different clinical forms of leishmaniasis [27]. Another study reported that Th1 cytokines and keratinocyte growth factor play a critical role in pseudoepitheliomatous hyperplasia indicate that the regulation of leukocyte activation and its recruitment plays a fundamental role in the production and maintenance of this epidermis lesion, through the production of TNF-α and IFN-γ [28].

In order to deep knowledge regarding to the in situ cellular immune response in the NUCL, the present study evaluate some parameters of the cellular immune response with special
reference to lymphocytes subsets by immunohistochemistry. It is important to note that little is known about this clinical form caused by L. (L.) infantum chagasi in Central America [4]; in this way, this study contributes substantially to knowledge about the pathogenesis of this rare clinical form of human infection cause by viscerotropic strain of parasite. The immunohistochemical analysis of the lesions evidenced the presence of a mononuclear infiltrate in the dermis, mainly lymphocytes, characterized by the presence of CD8+ T cells, CD4+ T cells, NK lymphocytes (CD56<sup>+</sup>) and B lymphocytes (CD20<sup>+</sup>). Macrophages (CD68<sup>+</sup>) were also present in considerable numbers but in lower cell density than CD8<sup>+</sup> T lymphocytes. These results confirm the findings already reported [12] that describe the presence of mononuclear inflammatory infiltrate, mainly formed by lymphocytes and to a lesser extent by macrophages.

We observed a strong and positive correlation between CD4<sup>+</sup> T and CD8<sup>+</sup> T cells and a ratio between these cell types of 0.38, showing that individuals affected by NUCL have a significantly higher number of CD8<sup>+</sup> T lymphocytes in relation to CD4<sup>+</sup> T lymphocytes. However, Da Cruz et al. [29,30] showed that in individuals affected by cutaneous leishmaniasis caused by dermotropic strain, L. (V.) braziliensis, the CD4:CD8 ratio was 2.5 in active disease and only observed a ratio of 0.8 during and at the end of the treatment, suggesting that CD8<sup>+</sup> T lymphocytes could be involved in the healing process.

Positive correlation of CD8<sup>+</sup> T and CD4<sup>+</sup> T cells with IFN-γ<sup>+</sup> cells was observed in our study, suggesting that in NUCL, these cellular types could play an important role in the production of IFN-γ<sup>+</sup>, mainly CD8<sup>+</sup> T lymphocytes since they are the predominant cells in the inflammatory infiltrate and are presented in equivalent numbers of IFN-γ<sup>+</sup> cells. IFN-γ<sup>+</sup> is the main cytokine activator of macrophages that, once activated, are able to produce toxic metabolites and control parasitism, thus showing that CD8<sup>+</sup> T cells could play a protective role in this rare cutaneous form of leishmaniasis. The ability of CD8<sup>+</sup> T cells to contribute to the protective or pathological mechanisms in cutaneous leishmaniasis is directly associated with its effector functions. Thus, CD8<sup>+</sup> T cells are protective when they produce IFN-γ, which activates macrophages to lyse parasites but are associated with tissue injury when they exert cytolytic or cytotoxic activity [31,32]. Studies have shown that in cutaneous and mucocutaneous leishmaniasis caused by L. (V.) braziliensis, CD8<sup>+</sup> T cells contribute to the exacerbation of the disease due to their cytolytic function, and the severity of the disease in these patients is directly associated with the increase in the number of CD8<sup>+</sup> T cells expressing granzyme [31–34]. On the other hand, there is evidence that CD8<sup>+</sup> T cells are essential for the control of primary and secondary infection, since activated CD8<sup>+</sup> T cells produce chemokines and are an important source of IFN-γ, which modulates granuloma formation and contributes to the reduction in parasitic load [32,34]. These data are similar to those observed in our study, since the inflammatory process of the skin lesion led to granuloma formation in 60% of the cases with discrete tissue parasitism in 100% of the cases. Since the parasitism of skin lesions is very low, as already reported by our group [12], no correlation between parasite load and intensity of the inflammatory infiltrate, evolution time, and the density of the different markers studied was observed.

In PKDL lesion, that is clinically characterized by the presence of hypopigmented macules, erythematous papules and nodules on the skin, and histologically by inflammatory infiltrate in the dermis with consist of a mixture of lymphocytes, histiocytes and plasma cells; IL-10–producing CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes are important protagonists in the immunopathogenesis [35,36]. It was shown through up regulated IL10 production by CD8<sup>+</sup> T cells in PKDL patients and some other studies has also provided evidence for the role of IL-10 producing TGF-β in immunopathogenicity which can regulate the IFN-γ dominant protective Th1 response in patients both in peripheral blood mononuclear cells and in dermal lesions of PKDL patients. Additionally, there are reports on a mixed T cell response in PKDL patients since they presented upregulated production of both IL-10 and TNF-α [35,37].

A very interesting finding in our study is that the number of macrophages (CD68<sup>+</sup> cells) was equivalent to the number of iNOS<sup>+</sup> cells, the enzyme responsible for the production of nitric oxide, a molecule with leishmanicidal activity, which suggests that all the macrophages in the lesion are likely activated, however, further studies using double staining are still needed. In addition to this result, we found a positive correlation between CD68<sup>+</sup> cells and iNOS<sup>+</sup> cells, as well as between CD68<sup>+</sup> cells and IFN-γ<sup>+</sup> cells, which could suggest the joint participation of elements that contribute to cellular activation and control of tissue parasitism [38,39]. These results point to a very effective local cellular immune response, since the lesions observed in all patients are small and scarce parasitism, regardless of the intensity of the infiltrate, the presence of granulomas and the time of evolution [12].

Th1-type CD4<sup>+</sup> T lymphocytes are also able to secrete IFN-γ among other inflammatory cytokines, such as IL-2 and TNF-α, activating the cellular immune response towards healing and protection. On the other hand, Th2-type CD4<sup>+</sup> T lymphocytes secrete anti-inflammatory cytokines, such as IL-4, IL-5, IL-6, IL-10 and IL-13, targeting the cellular immune response of the host to susceptibility to infection [40,41].

Conversely, our previous report using the same biopsies of this study showed very few numbers of IL-10<sup>+</sup> cells, which did not present correlation to T CD4<sup>+</sup> cells [14]; so, the present results suggest a participation, albeit discreet, of Th1-type CD4<sup>+</sup> T cells producing IFN-γ contributing to infection control. Corroborating this interpretation, our results showed a discrete participation of B lymphocytes (CD20<sup>+</sup> cells) in the NUCL, cells that proliferate and produce immunoglobulins by stimulation of Th2 type CD4<sup>+</sup> T lymphocytes [42–44]. In addition, we showed that patients with NUCL produce very little antibody, since only 19% of them were seropositive and always had low titers of specific IgG or IgM antibodies. On the other hand, 56% of these patients showed a strongly positive intradermal Montenegro reaction [23], reinforcing the findings of an effective cellular immune response of the host against L. (L.) infantum chagasi.
Despite the efficient response in the skin of individuals affected by NUCL, the total control of the tissue parasitism and the spontaneous healing of the lesion do not occur. The discrete parasite persistence is likely linked to the participation of regulatory cells through the in situ production of TGF-β in the lesion of NUCL [14].

Conclusion

In summary, this study characterize the main mononuclear inflammatory cells present in dermal cutaneous lesions caused by L. (L.) infantum chagasi, which were formed mainly by CD8+ T lymphocytes, followed by macrophages mostly iNOS+, a response that could be mediated by the main inflammatory cytokine, IFN-γ. The results highlight a pivotal contribution of CD8+ T lymphocytes in orchestrating host protection against L. (L.) infantum chagasi infection in the skin and add new knowledge on the immunopathology of NUCL. Nevertheless, further studies are necessary to corroborate the protective involvement of CD8+ T lymphocytes in the immunopathogenesis of NUCL.

Acknowledgments

We would like to thank BSc Thaise Yumie Tomokane for the statistical analysis support. Thanks are also due to the staff of the Health Unit of the Municipality of Amapala, especially to Dr. Arnaldo Carranza (in memoriam) and Jessica Cardenas, and Orocuina for their unconditional support; and staff of the Laboratory of Pathology of the University School Hospital of National Autonomous University of Honduras, especially Dr. Mazlova Toledo. Finally, we also thank the Laboratory of Histology of the Department of Pathology, University of São Paulo Medical School, for their support in processing of the biopsies.

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Funding

The present research was supported by the São Paulo Research Foundation (FAPESP) grants #2014/50315-0, #2015/01547-7, #2017/24834-9, #2018/04698-6, Dirección de Investigación y Posgrados of the UNAH grant #02–2015. GA is the recipient of a scholarship from CAPES (Social Demand) and Laboratorio de Patologia de Molestias Infecciosas (LIM50 HC-FMUSP). ML is the recipient of a research fellowship from the National Council for Scientific and Technological Development (CNPq), grant # 302174/2017-6.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

CS and GA equally contributed to this work. CS, GA, FS and ML carried out experiment design and development. CZ, WS and SA were responsible for selection of individual, clinical and laboratory diagnosis, and medical support. CS, GA and ML conducted data analysis. CS, GA and ML participated in manuscript writing. CC, CZ, WS and FS carried out manuscript revision. ML, CC and WS were responsible for seeking financial support. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This project was approved by the Research Ethics Committee of the Graduate Program of Infectious and Zoonotic Diseases of the National Autonomous University of Honduras (research protocol no. 03-2014) and by the Research Ethics Committee of the Medical School of the University of São Paulo (research protocol no. 051/15). Written informed consent was obtained from all participants.

Consent for publication

Not applicable.

References

1. Belli A, García D, Palacios X, Rodriguez B, Valle S, Videa E, et al. Widespread atypical cutaneous leishmaniasis caused by Leishmania (L.) chagasi in Nicaragua. Am J Trop Med Hyg. 1999 Sep;61(3):380-5.
2. Noyes H, Chance M, Ponce C, Ponce E, Maingon R. Leishmania chagasi: genotypically similar parasites from Honduras cause both visceral and cutaneous leishmaniasis in humans. Exp Parasitol. 1997 Mar;85(3):264-73.
3. OPS. Manual de manejo de enfermedades parasitarias prioritarias en Honduras.; Segunda.; OPS (Organizacion Panamericana de la Salud): Tegucigalpa, 2009; ISBN 9789999264532.
4. Ponce C, Ponce E, Morrison A, Cruz A, Kreutzler R, McMahon-Pratt D, et al. Leishmania donovani chagasi: new clinical variant of cutaneous leishmaniasis in Honduras. Lancet. 1991 Jan 12;337(8733):67-70.
5. Zeledón R, Macaya G, Ponce C, Chaves F, Murillo J, Bonilla JA. Cutaneous leishmaniasis in Honduras, Central America. Trans R Soc Trop Med Hyg. 1982;76(2):276-7.
6. Santos K, Bermúdez J, Lutz EL, Alger J, Sierra M, Fajardo D. Estudio Clínico-epidemiológico de leishmaniasis cutánea atípica en Reitoca, zona endémica del sur de Honduras. Rev Med Post Grados Med. 2006;9:47-57.
7. Campos-Ponce M, Ponce C, Maingon RDC, Leishmania chagasi/infantum: further investigations on Leishmania tropism in atypical cutaneous and visceral leishmaniasis foci in Central America. Exp Parasitol. 2005 Apr;109(4):209-19.
8. Salvioni OD, Pereira J, Sander MG, Gómez CV. Molecular detection of Leishmania infantum in atypical cutaneous lesions from paraguayan patients. J Dermatolog Clin Res. 2017 May;5:1104.
9. Aquino TA, Sales Martins S, Gomes CM, Oliveira J, Da Motta C, Graziani D, et al. First case report of cutaneous Leishmania infantum caused by Leishmania (Leishmania) infantum in a Brazilian patient treated with adalimumab. J Clin Exp Dermatol Res. 2014 Jan;5(6).
10. Castro LS, Franca AO, Ferreira EC, Hans Filho G, Higa Jr MG, Gontijo CMF, et al. Leishmania infantum as a causative agent of cutaneous leishmaniasis in the state of Mato Grosso do Sul, Brazil. Rev Inst Med Trop Sao Paulo. 2016;58:23.
11. Lyra MR, Pimentel MIF, Madeira MF, Antonio LF, Lyra JPM, Fagundes A, et al. First report of cutaneous leishmaniasis caused by Leishmania (Leishmania) infantum chagasi in an urban area of Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo. 2015 Sep-Oct;57(5):451-4.
12. Sandoval Pacheco CM, Araujo Flores GV, Favero Ferreira A, Sosa Ochoa W, Ribeiro da Matta VL, Zúñiga Valeriano C, et al. Histopathological features of skin lesions in patients affected by non-ulcerated or atypical cutaneous leishmaniasis in Honduras, Central America. Int J Exp Pathol. 2018 Oct;99(5):249-57.

13. Araujo Flores GV, Sandoval Pacheco CM, Sosa Ochoa W, Castro Gomes CM, Zúñiga C, Corbett CP, et al. Th17 lymphocytes in atypical cutaneous leishmaniasis caused by Leishmania (L.) infantum chagasi in Central America. Parasite Immunol. 2020 Nov;42(11):1-6.

14. Araujo Flores GV, Sandoval Pacheco CM, Tomokane TY, Sosa Ochoa W, Zúñiga Valeriano C, Castro Gomes CM, et al. Evaluation of Regulatory Immune Response in Skin Lesions of Patients Affected by Nonulcerated or Atypical Cutaneous Leishmaniasis in Honduras, Central America. Mediators Inflamm. 2018;2018:1-7.

15. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz. 2004 May;99(3):239-51.

16. Silveira FT, Lainson R, De Castro Gomes CM, Laurenti MD, Corbett CEP. Immunopathogenetic competences of Leishmania (V) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol. 2009 Jul 10;31(8):423-31.

17. Silveira FT, Muller SR, de Souza AAA, Lainson R, Gomes CMC, Laurenti MD, et al. Revisão sobre a patogenia da leishmaniose tegumentar americana na Amazônia, com ênfase à doença causada por Leishmania (V) braziliensis e Leishmania (L.) amazonensis. Rev Para Med. 2008;22(1):9-20.

18. Aguado M, Espinosa P, Romero-Mate A, Tardio JC, Córdoba S, Borbujo J. Brote de leishmaniasis cutánea en el municipio de Fuenlabrada. Actas Dermosifiliogr. 2013;104(4):334-42.

19. García-Almagro D. [Cutaneous leishmaniasis]. Actas Dermosifiliogr. 2005 Jan-Feb;96(1):193-8. [Article in Spanish].

20. Del Giudice P, Marty P, Lacour JP, Perrin C, Pratlong F, Haas H, et al. Cutaneous leishmaniasis due to Leishmania infantum. Case reports and literature review. Arch Dermatol. 1998 Feb;134(2):193-8.

21. Kroidl A, Kroidl I, Bretzel G, Löscher T. Non-healing old world cutaneous leishmaniasis caused by Leishmania infantum in nondiagnostic granulomatous lesions: report of a series of patients from a Western Mediterranean area. Br J Dermatol. 2009 Jul;160(7):1543-54.

22. Maniscalco M, Noto G, Zichichi L, Veraldi S. Multifocal cutaneous leishmaniasis: a new clinical presentation of the disease. Acta Derm Venereol. 2006;87(3):275-6.

23. Sosa-Ochoa W, Zúñiga C, Chaves LF, Araujo Flores GV, Sandoval Pacheco CM, Ribeiro da Matta VL, et al. Clinical and immunopathological features of human Leishmania (L.) infantum-infection, novel insights Honduras, Central America. Pathogens. 2020 Jul 10;31(8):423-31.

24. Martín-Ezquerra G, Fisa R, Riera C, Rocamora V, Fernández-Casado A, Barranco C, et al. Role of Leishmania spp. infection in nondiagnostic cutaneous granulomatous lesions: report of a series of patients from a Western Mediterranean area. Br J Dermatol. 2009 Aug;161(2):320-5.

25. Couppié P, Clyti E, Sainte-Marie D, Dedet JP, Carme B, Pradinaud R. Disseminated cutaneous leishmaniasis due to Leishmania guyanensis case of a patient with 425 lesions. Am J Trop Med Hyg. 2004 Nov;71(5):558-60.

26. González K, Díaz R, Ferreira AF, García V, Paz H, Calzada JE, et al. Histopathological characteristics of cutaneous lesions caused by Leishmania Viannia panamensis in Panama. Rev Inst Med Trop Sao Paulo. 2018;60:e8.

27. Scorza BM, Wacker MA, Messingham K, Kim P, Klingelhoft A, Fairley J, et al. Differential activation of human keratinocytes by Leishmania species causing localized or disseminated disease. J Invest Dermatol. 2017 Oct;137(10):2149-56.

28. Akilov OE, Donovan MJ, Stepinac T, Carter CR, Whitcomb JP, Hasan T, et al. T helper type 1 cytokines and keratinocyte growth factor play a critical role in pseudopoeitheliomatous hyperplasia initiation during cutaneous leishmaniasis. Arch Dermatol Res. 2007 Sep;299(7):315-25.

29. Da-Cruz AM, Conceição-Silva F, Bertho AL, Coutinho SG. Leishmania-reactive CD4+ and CDB+ T cells associated with cure of human cutaneous leishmaniasis. Infect Immun. 1994 Jun;62(6):2614-8.

30. Da-Cruz AM, Bittar R, Mattos M, Oliveira-Neto MP, Nogueira R, Pinheiro Ribeiro V, et al. T-cell-mediated immune responses in patients with cutaneous or mucosal leishmaniasis: long-term evaluation after therapy. Clin Diag Lab Immunol. 2002 Mar;9(2):251-6.

31. Novais FO, Carvalho LP, Graff JW, Beiting DP, Ruthel G, Roos DS, et al. Cytotoxic T cells mediate pathology and metastasis in cutaneous leishmaniasis. PLoS Pathog. 2013;9(7):e1003504.

32. Novais FO, Scott P, CD4+ T cells in cutaneous leishmaniasis: the good, the bad, and the ugly. Semin Immunopathol. 2015 May;37(3):251-9.

33. da Silva Santos C, Brodsky CI. The role of CD4 and CDB T cells in human cutaneous leishmaniasis. Front Public Health. 2014;2:165.

34. Stäger S, Rafati S. CD8(+) T cells in Leishmania infections: friends or foes? Front Immunol. 2012 Jan 24;3:5.

35. Ganguly S, Das NK, Panja M, Pal S, Modak D, Rahman M, et al. Increased levels of interleukin-10 and IgG3 are hallmarks of Indian post-kala-azar dermal leishmaniasis. J Infect Dis. 2008 Jun 15;197(12):1762-71.

36. Singh AK, Verma N, Das R, Krishna VN, Bimal P. Unresolved issues in innate immune response in post kala azar dermal leishmaniasis (PKDL). Sci J Immunol Immunother. 2017;2(1):18-21.

37. Ansari NA, Ramesh V, Salotra P. Interferon (IFN)-g, tumor necrosis factor-a, interleukin-6, and IFN-g receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis. 2006 Oct 1;194(7):958-65.

38. Sanches FP, Tomokane TY, da Matta VL, Marcondes D, Corbett CEP, Laurenti MD. Expression of inducible nitric oxide synthase in macrophages inversely correlates with parasitism of lymphoid tissues in dogs with visceral leishmaniasis. Acta Vet Scand. 2014 Sep;56:57.

39. Castellano LR, Correia D Filho, Argiro L, Dessein H, Prata A, Dessein A, et al. Th1/Th2 immune responses are associated with active cutaneous leishmaniasis and clinical cure is associated with strong interferon-γ production. Hum Immunol. 2009 Jun;70(6):383-90.

40. Carvalho LP, Passos S, Schriefer A, Carvalho EM. Protective and pathologic immune responses in human tegumentary leishmaniasis. Front Immunol. 2012 Oct 4;3:301.

41. Blank C, Bogdan C, Bauer C, Erb K, Moll H. Murine epidermal Langerhans cells do not express inducible nitric oxide synthase. Eur J Immunol. 1996 Apr;26(4):792-6.

42. Mutisio JM, Macharia JC, Gicheru MM, Owuor HA. Immunology of leishmaniasis. Sci Parasitol. 2013 Jun;14:51-61.

43. Ampuero J. Leishmaniasis módulos técnicos serie documentos monográficos n°8 Lima. Minist Salud. 2000:1-80.

44. López SPA, Restrepo SMR. Respuesta inmune en infecciones humanas por Leishmania spp. latrea. 2000 Mar;13(3):167-78.